BTIG analyst Jeet Mukherjee has maintained their bullish stance on NRIX stock, giving a Buy rating today.
Jeet Mukherjee has given his Buy rating due to a combination of factors that suggest promising developments for Nurix Therapeutics. The company is expected to provide updates on its NX-5948 program at the EHA, which could demonstrate continued durability of response in patients and reveal pivotal study design details for CLL settings. Additionally, Nurix’s IRAK4 program is anticipated to enter clinical trials this year, and the STAT6 program may benefit from positive developments in a similar program currently in the clinic.
Moreover, Nurix has secured a partnership with Sanofi, which has licensed a novel drug discovery program targeting a transcription factor relevant to autoimmune diseases. This collaboration could lead to significant advancements and financial gains, as evidenced by the recent $15 million license extension fee. Financially, Nurix is in a strong position with substantial cash reserves, providing a runway into the first half of 2027, which supports its ongoing and future projects.
In another report released today, Barclays also maintained a Buy rating on the stock with a $31.00 price target.
NRIX’s price has also changed dramatically for the past six months – from $22.000 to $9.260, which is a -57.91% drop .